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Abstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, 
with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial pros-
tatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary 
tract infection, and acute urinary retention. Medical treatments of symptomatic BPH include; 
1) the 5α-reductase inhibitors, 2) the α1-adrenergic antagonists, and 3) the combination of a 
5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists 
relax the smooth muscle of the prostate and bladder neck without affecting the detrussor 
muscle of the bladder wall, thus decreasing the resistance to urine ﬂ  ow without compromis-
ing bladder contractility. Clinical trials have shown that α1-adrenergic antagonists decrease 
LUTS and increase urinary ﬂ  ow rates in men with symptomatic BPH, but do not reduce the 
long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase 
decrease production of dihydrotestosterone within the prostate resulting in decreased prostate 
volumes, increased peak urinary ﬂ  ow rates, improvement of symptoms, and decreased risk of 
acute urinary retention and need for surgical intervention. The combination of a 5α-reductase 
inhibitor and a α1-adrenergic antagonist reduces the clinical progression of BPH over either 
class of drug alone.
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Introduction 
Benign prostatic hyperplasia (BPH) refers to stromal and glandular epithelial hyperpla-
sia that occurs in the zone of the prostate that surrounds the urethra. Histopathologic 
BPH is often associated with lower urinary tract symptoms (LUTS), characterized by 
urinary frequency and urgency, a sensation of incomplete bladder emptying, a weak 
and interrupted urinary stream, straining to initiate urination, and nocturia. The preva-
lence of BPH increases with increasing age, and moderate to severe symptoms occur 
in up to 40% of men after age 60. Symptoms are evaluated with validated instruments 
such as the American Urologic Association (AUA) Symptom Index. Each of seven 
symptoms (frequency, urgency, weak stream, intermittency, incomplete emptying, 
straining to urinate, and nocturia) are scored by the patient on a 0–5 scale based on 
their frequency. A score of less than 7 indicates mild symptoms; a score of 8–19 indi-
cates moderate symptoms, and a score of greater than 19 indicates severe symptoms. 
In addition to symptoms that may have a negative impact on the quality of life, BPH 
can result in acute urinary retention, recurrent urinary tract infections (UTI), bladder 
stones, urinary incontinence, gross hematuria, and renal failure.
The natural history of BPH is unpredictable in individual men. In a study of men 
who were followed expectantly for 5 years without treatment, 31% reported symp-
tomatic improvement whereas 16% reported symptomatic worsening (Ball et al 1981). 
Men with symptomatic BPH have a 23% lifetime risk of developing acute urinary Clinical Interventions in Aging 2007:2(1) 100
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retention if left untreated (Jacobsen et al 1996). A man over 
age 60 years with obstructive symptoms has a 20-year prob-
ability of undergoing surgery related to the prostate of 39% 
(Arrighi et al 1991).
The AUA and the European Association of Urology have 
published recommendations for the evaluation of men with 
LUTS, and the treatment of men with symptomatic BPH. 
Medical therapies recommended by these two organizations 
include the α1-adrenergic antagonists terazosin, doxazocin, 
tamsulosin, and alfuzosin and the 5α-reductase inhibitors 
ﬁ  nastereide and dutasteride (Roehrborn et al 2003).
Selective α1-adrenergic antagonists relax the smooth 
muscle of the prostate and bladder neck without affecting 
the detrussor muscle of the bladder wall, thus decreasing the 
resistance to urine ﬂ  ow without compromising bladder con-
tractility. Randomized, placebo-controlled clinical trials have 
shown that α1-adrenergic antagonists decrease LUTS and 
increase urinary ﬂ  ow rates in men with symptomatic BPH. 
However, a positive placebo effect was also demonstrated 
for both symptoms score and peak urinary ﬂ  ow rates in these 
trials. Common side effects include dizziness, headache, 
asthenia, and postural hypotension, which occur in 5%–9% 
of patients (Roehrborn and Schwinn 2004). Tamsulosin is 
the most uroselective α1-adrenergic antagonist approved for 
use in the treatment of symptomatic BPH. Clinical trials have 
shown postural hypotension was observed less frequently 
with tamsulosin than with either terazosin or doxazocin 
(Lepor 1998).
Dihydrotestosterone (DHT) is the product of the conver-
sion of testosterone by the enzyme 5α-reductase, and is pro-
duced in the tissues of the liver, skin and organs that originate 
from the mesonephric duct, such as the prostate. Within the 
prostate, locally produced DHT acts in a paracrine fashion 
to stimulate growth. Inhibitors of 5α-reductase decrease 
production of DHT within the prostate resulting in decreased 
prostate volume, increased peak urinary ﬂ  ow rates, and 
improvement in symptoms scores. Studies have also shown 
that 5α-reductase inhibitors reduce serum levels of pros-
tate speciﬁ  c antigen and reduce the overall risk of prostate 
cancer (Thompson et al 2003). Side effects of 5α-reductase 
inhibitors include erectile dysfunction, decreased libido, 
ejaculatory dysfunction, and gynecomastia, which occur in 
less than 5% of patients (Abramowicz 2002). Dutasteride 
inhibits both type 1 and type 2 5α-reductase isoenzymes, 
whereas ﬁ  nasteride inhibits only type 2.
Combination therapy with the α1-adrenergic antagonist 
doxazocin and the 5α-reductase inhibitor ﬁ  nasteride has 
been shown to signiﬁ  cantly reduce the overall risk of clinical 
progression of BPH compared with the use of either drug 
alone. The Medical Therapy of Prostate Symptoms (MTOPS) 
Trial studied 3047 men age 50 and older with moderate to 
severe symptomatic BPH for a period of 4.5 years. Patients 
were randomized to receive 1) ﬁ  nasteride and placebo, 2) 
doxazocin and placebo, 3) ﬁ  nasteride and doxazocin, and 4) 
both placebos. The primary outcome was clinical progression 
of BPH. Secondary outcome measures included changes in 
AUA symptom score and peak urinary ﬂ  ow rate, and the risk 
of receiving surgical therapy for symptomatic BPH.
Compared with the placebo group, the risk of clinical 
progression of BPH, reported as rate per 100 person-years, 
was reduced by 39% in the doxazocin group (p < 0.001), 
by 34% in the ﬁ  nasteride group (p = 0.002), and by 66% 
in the combination therapy group (p < 0.001). The risk of 
clinical progression in the combination therapy group was 
signiﬁ  cantly reduced compared with either the doxazocin 
or the ﬁ  nasteride group (p < 0.001). Reduction in the AUA 
Symptom Index score occurred in all groups and was sig-
niﬁ  cantly greater than placebo in all of the drug treatment 
groups. Improvement in the symptoms score after 4 years 
was signiﬁ  cantly greater in the combination therapy group 
than either the doxazocin group (p = 0.006) or in the ﬁ  naste-
ride group (p < 0.001). Peak urinary ﬂ  ow rates increased in 
all drug groups over the placebo group (p < 0.001 for each 
pair wise comparison). Compared with the placebo group, 
the risk of receiving surgical therapy for symptomatic BPH 
was reduced by 64% in the ﬁ  nasteride group (p < 0.001), 
and by 67% in the combination therapy group (p < 0.001) 
(McConnell et al 2003).
Pharmacology, mode of action, and 
pharmacokinetics of dutasteride
Dutasteride is in a drug class known as 17β-substituted 
4-aza-steroids with the chemical name (5α, 17β)-N {2, 5, 
bis(triﬂ  uoromethyl) phenyl}-3-oxo-4-azaandrost-1-ene-17-
carboxamide. The structural formula is shown in Figure 1. It 
is a competitive inhibitor of type 1 and type 2 5α-reductase 
isoenzymes. It forms a stable complex with a slow rate of 
dissociation and does not bind the androgen receptor. The 
bioavailability of dutasteride is approximately 60% and peak 
serum concentration is achieved after 2–3 hours. The time to 
steady state is dose dependent, and at a dose of 0.5 mg/day 
is approximately 3 months. More than 99.5% of circulating 
dutasteride is bound to plasma proteins, and has a volume 
of distribution of 300 to 500 liters. Clearance is linear at 
0.58 liters/hour, resulting in a half-life of up to 5 weeks. 
Pharmacokinetic data is summarized in Table 1. Dutasteride Clinical Interventions in Aging 2007:2(1) 101
Use of dustasteride in BPH
is detectable (>0.1 ng/mL) in the serum 4–6 months af-
ter discontinuation of treatment. The drug is extensively 
metabolized by cytochrome-P3A4 in the liver and is excreted 
mainly in the feces. Only trace amounts are excreted in the 
urine. Following dosing to steady state, 5 major metabolites 
are detectable in the serum. The major metabolite, 6β-
hydroxydutasteride, has pharmacological activity compa-
rable with dutasteride (Bramson et al 1997).
Caution should be used when administering the drug in 
patients with hepatic impairment, and in patients who take 
drugs that inhibit cytochrome-P3A4 (verapamil, diltiazem, 
and ritonavir) because the pharmacokinetics and risk of side 
effects may be altered. No other signiﬁ  cant drug interactions 
have been identiﬁ  ed.
In three pooled two-year studies, the most frequent side 
effects were impotence, decreased libido, gynecomastia, 
and ejaculatory dysfunction. The incidence of side effects 
compared with placebo was increased from 4% to 7.3% for 
impotence, 2.1% to 4.2% for decreased libido, 0.7% to 2.3% 
for gynecomastia, and 0.8% to 2.2% for ejaculatory dysfunc-
tion (Roehrborn et al 2002).
No dose adjustment is necessary in the elderly. Of 2617 
men treated with dutasteride in three pivotal studies, 60% 
were age 65 and over and 15% were age 75 and over. In 
these studies no overall difference in safety or efﬁ  cacy was 
observed between older and younger patients. No change 
in bone mineral density as measured on dual energy X-ray 
absorptiometry was observed, when compared with placebo. 
Plasma lipid proﬁ  les were unaffected (PDR 2004).
Dutasteride is not indicated for use in women and the 
pharmacokinetics have not been investigated in patients 
younger than 18 years. Due to potential adverse effects 
on normal development of the male reproductive tract, 
use of dutasteride should be avoided in men less than 18 
years of age, and is absolutely contraindicated in women of 
reproductive age (PDR 2004).
Efﬁ  cacy and safety of dutasteride
The efﬁ  cacy and safety of dutasteride was studied in three 
parallel, randomized, placebo-controlled trials over a period 
of two years. A total of 4325 men age 50 years or older with 
moderate to severe symptomatic BPH (AUA symptom score 
of 12 or more and peak urinary ﬂ  ow rate of 15 ml/sec or less) 
and prostate volume greater than 30 cm3 were randomized 
to receive either dutasteride 0.5 mg/day or placebo. Primary 
endpoints measured were changes in prostate volume, peak 
urinary ﬂ  ow rate, risk of surgical intervention, safety and 
tolerability, and measurements of serum prostate-speciﬁ  c 
antigen (PSA), testosterone, and DHT (Roehrborn et al 
2002).
The mean improvement in symptom score in the placebo 
groups was 2.3 (± 6.8) to 14.7 (± 7.2) from a baseline of 17.1 
(± 6.1, p < 0.001). In the dutasteride groups, a 4.5-point (± 6.6) 
improvement to a mean of 12.2 (± 6.6) was signiﬁ  cant com-
pared with baseline of 17.0 (± 6.0, p < 0.001) and compared 
with placebo groups (p < 0.001). Peak urinary ﬂ  ow rates 
in the placebo groups increased by 0.6 ml/sec (± 4.7) to 
11.2 ml/sec (± 4.8), which was signiﬁ  cant compared with 
baseline of 10.4 ml/sec (± 3.6, p < 0.001). Peak urinary 
ﬂ  ow rates in the dutasteride groups increased by a mean 
of 2.2 ml/sec (± 5.2) to 12.5 (± 5.6), which was signiﬁ  cant 
compared with baseline of 10.1 ml/sec (± 3.5, p < 0.001), 
and to the placebo groups (p < 0.001). After 24 months 
of therapy, the mean total prostate volume increased by 
12.4% in the placebo groups and decreased by 20.4% in the 
dutasteride groups (p < 0.001). The relative risk of acute 
urinary retention in the dutasteride groups compared with 
the placebo groups was 0.43, or a risk reduction of 57% 
(p < 0.001). The relative risk of surgical intervention in the 
dutasteride groups compared with the placebo groups was 
0.52, or a risk reduction of 48% (p < 0.001). Signiﬁ  cant 
decreases in serum DHT, PSA, and an increase in serum 
testosterone were noted in the dutasteride groups compared 
with the placebo groups (p < 0.001 for each comparison) 
(Roehrborn et al 2002).
Table 1 Pharmacokinetics of dutasteride 0.5 mg/day
Bioavailability 60% 
Steady state  3 months
Peak serum concentration  2–3 hours
Volume of distribution  511 liters
Elimination half-life  5 weeks 
*
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Figure 1 Dutasteride structural formula.Clinical Interventions in Aging 2007:2(1) 102
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Adverse events attributed to the study drug were reported 
in 14% of men in the placebo groups and in 19% of men in the 
dutasteride groups. A higher proportion of men in the dutas-
teride groups than in the placebo groups reported impotence, 
reduced libido, ejaculatory dysfunction, and gynecomastia 
(Roehrborn et al 2002). Results are summarized in Table 2.
Data from several open-label extensions of the above 
three parallel, randomized placebo-controlled trials have 
recently been reported. These studies show continued toler-
ability and efﬁ  cacy after 48 months of treatment. In these 
trials less than 1% of the men withdrew from the open-label 
extension because of sexual function adverse events. Ap-
proximately 1% of men withdrew because of gynecomastia. 
Patients who received dutasteride during both study phases 
showed greater improvement in symptom scores and urinary 
peak ﬂ  ow rates than those initially receiving placebo (Roeh-
rborn et al 2004, 2005; Schulman et al 2006).
Effect on quality of life
Data regarding the impact on quality of life of the 4325 men 
in the three randomized, double-blind, placebo controlled, 
2-year studies detailed above have also been reported. At 2 
years, dutasteride, but not placebo, resulted in clinically and 
statistically signiﬁ  cant improvements from baseline in the 
BPH Impact Index (BII) score after 6 months of treatment. 
This net improvement from baseline increased from 6 months 
to 2 years (O’Leary et al 2003).
Additional data were recently reported from a separate 
prospective, multi-center, open-label study evaluating the 
improvement in symptoms and quality of life in patients 
with symptomatic BPH treated with dutasteride. Patients 
received dutasteride 0.5 mg/day for 24 weeks. The primary 
endpoint was the proportion of patients who achieved at 
least a 3-point decrease from baseline in International 
Prostate Symptom Score (IPSS). The secondary endpoints 
were changes in quality of life (IPSS item 8) and patient 
discomfort and satisfaction, assessed using the visual ana-
logue scale (VAS). 
A total of 366 patients from 72 centers were included 
in the study. After 24-weeks of treatment with dutasteride, 
72.5% of patients achieved at least a 3-point reduction in 
IPSS. The mean IPSS score decreased from 15.3 (± 6.4) 
at baseline to 9.1 (± 5.6, p < 0.001) at 24 weeks. Patients 
with more severe symptoms had a higher probability of 
improvement in the IPSS. There were statistically signiﬁ  cant 
decreases in all individual IPSS items, with greater improve-
ment seen in items related to irritative and obstructive voiding 
symptoms than in those items related to storage symptoms. 
Patient quality of life improved as assessed by IPSS 
item 8 with a mean improvement of 38.7% from base-
line (p < 0.001). Patient discomfort and satisfaction also 
significantly improved. The mean VAS for discomfort 
decreased from 48.9 at baseline to 28.6 (p < 0.001) at 24 
weeks. Patient VAS scores for satisfaction increased from a 
baseline at both 12 and 24 weeks (p < 0.001). 
Overall, 77 (19%) patients had at least one adverse event 
related to dutasteride during the study period, including 
erectile dysfunction (7%), decreased libido (4%), and gyne-
comastia (2%) (Desgrandchamps et al 2006).
Dutasteride in prostate cancer 
prevention and treament
An in-depth discussion of the role of 5α-reductase inhibitors 
in the prevention and treatment of prostate cancer is beyond 
the scope of this review, however the clinical implications 
of long-term use of ﬁ  nasteride or dutasteride in the treatment 
of BPH must be considered in light of new information from 
recent trials.
In the Prostate Cancer Prevention Trial (PCPT) 18 882 
men aged 55 years or older with a PSA of 3.0 ng/ml or less 
were randomized to receive ﬁ  nasteride 5 mg or placebo daily 
for 7 years. Prostate biopsies were performed at the end of the 
7 year study period, or if the annual PSA level (adjusted for 
the effect of ﬁ  nasteride) was greater than 4 ng/ml, or if the 
digital rectal exam (DRE) was suspicious for prostate cancer. 
The primary endpoint measure was the diagnosis of prostate 
cancer. The study was terminated 15 months early on the rec-
ommendations of the data and safety monitoring committee 
because the study objective had been met. Prostate cancer 
was detected in 18.4% of men in the ﬁ  nasteride group and in 
24.4% of men in the placebo group, a relative risk reduction 
of 24.8% (p < 0.001). However, of the men who developed 
prostate cancer, high-grade prostate cancer was reported in 
a higher proportion of men in the ﬁ  nasteride group than in 
the placebo group (37% versus 22%, p < 0.001) (Thompson 
et al 2003). Androgen deprivation therapy, including inhibi-
tion of DHT by ﬁ  nasteride, results in speciﬁ  c histopathologic 
changes in prostatic adenocarinoma, which can result in a 
Table 2  Adverse events from dutasteride efﬁ  cacy and safety 
study
 Dutasteride  Placebo
Impotence 7.3% 4.0%
Decreased libido  4.2%  2.1%
Ejaculation disorder  2.2%  0.8%
Gynecomastia 2.3%  0.7%Clinical Interventions in Aging 2007:2(1) 103
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“grading bias.” In the PCPT, most of the high-grade cancers 
were reported in the earlier phase of the study, a ﬁ  nding that 
is at odds with the development of more aggressive cancers 
with prolonged ﬁ  nasteride treatment (Bostwick et al 2004). 
An ongoing study, the Reduction by Dutasteride of Pros-
tate Cancer Events (REDUCE) Trial will use dutasteride in 
a group of men identiﬁ  ed at increased risk of developing 
prostate cancer to determine if this dual 5α-reductase in-
hibitor will be an effective chemoprevention agent. Eligible 
men must be between ages 50 and 75 and have a PSA be-
tween 2.5 ng/ml and 10 ng/ml (age 50–60 years) or between 
3.0 ng/ml and 10 ng/ml (age > 60 years), and a free PSA of 
25% or lower at baseline. Prostate biopsies will be performed 
at 2 years and at 4 years to evaluate for prostate cancer. 
Additionally, free and total PSA will be measured every 6 
months, with adjustment of the PSA of patients randomized 
to the dutasteride arm. The primary endpoint is biopsy-
proven prostate cancer after 2 and 4 years of treatment. The 
study also aims to address the issue of high-grade tumors 
prospectively.
As discussed above, dutasteride inhibits both type 1 
and type 2 5α-reductase isoenzymes, whereas ﬁ  nasteride 
inhibits only type 2. Type 2 5α-reductase is the predominant 
isoenzyme in normal and hyperplastic prostate tissue. Recent 
studies have shown that immunohistochemical staining of 
type 1 is enhanced in prostate cancer tissues compared 
with BPH epithelium. This suggests that a dual inhibitor 
of 5α-reductase isoenzymes, such as dutasteride, may be a 
reasonable agent to evaluate for prevention of prostate cancer 
(Gomella 2005).
As information from ongoing trials is compiled, 
physicians who recommend 5α-reductase inhibitors for the 
treatment of symptomatic BPH should discuss the effect of 
therapy on the histopathology of prostate biopsies and the 
potential for risk of high-grade prostate cancer with their 
patients.
In addition to its potential role in the prevention of pros-
tate cancer, dutasteride has been evaluated as a component 
of neoadjuvant androgen deprivation therapy before brachy-
therapy for prostate cancer. In a recently reported study, 31 
patients opted for cytoreductive therapy with bicalutamide 
50 mg and dutasteride 0.5 mg daily. All patients underwent 
transrectal ultrasound volumetric study of the prostate gland, 
with ellipsoid volume determination of the prostate gland and 
transition zone, before initiation of the neoadjuvant therapy 
and at 3 months after initiation. After the 3-month course of 
combination therapy, the average prostate volume decreased 
by 33.6% using the volumetric determination, and decreased 
by 34.6% using the ellipsoid volume determination. The 
average transition zone volume decreased from 20.8 cm3 
to 12.4 cm3, a reduction of 39.8% (Merrick et al 2006). 
Although these data are not the product of a randomized, 
placebo-controlled trial, the results are consistent with previ-
ous studies of androgen deprivation therapy, and dutasteride 
may be a reasonable alternative to the use of luteinizing 
hormone-releasing hormone (LHRH) agonists, which have 
been associated with major side effects
Conclusions
Dutasteride is the only dual inhibitor of 5α-reductase 
approved for use in the treatment of men with symptomatic 
BPH. Few drug interactions have been identiﬁ  ed. The use 
of this drug is contraindicated in men under age 18 and in 
women due to the potential adverse effects on normal de-
velopment of the male reproductive tract. Side effects occur 
in less than 5% of patients and include impotence, loss of 
libido, ejaculatory dysfunction, and gynecomastia. There is 
a potential risk of developing high-grade prostate cancer, al-
though the overall risk of prostate cancer is reduced. Ongoing 
trials may support the use of dutasteride in the prevention of 
cancer and its role in the treatment of prostate cancer is also 
being evaluated. Treatment in men with moderate to severe 
lower urinary tract symptoms results in improved symptoms, 
increased urinary ﬂ  ow rate, a reduced risk of urinary retention 
and need for surgical intervention, and an improvement in 
quality of life. Inhibition of 5α-reductase reduces the clinical 
progression of BPH, an effect that is further enhanced by the 
addition of an α1-adrenergic receptor antagonist.
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